This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Gilead Collaborates with Hookipa for HBV and HIV Therapies
by Zacks Equity Research
Gilead Sciences (GILD) collaborates with Hookipa Biotech AG for the development of immunization technologies for HBV and HIV diseases.
Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive
by Zacks Equity Research
AbbVie (ABBV) announces positive top-line results from the fifth phase III study on its JAK inhibitor, upadacitinib in moderate-to-severe rheumatoid arthritis.
Eli Lilly's Olumiant Gets FDA Nod for Rheumatoid Arthritis
by Zacks Equity Research
Eli Lilly (LLY) and its partner Incyte announce approval of their arthritis drug, Olumiant, in the United States. The drug will be available at two-fifth of the price of leading RA drugs.
Gilead & Galapagos Announce Positive Data on Filgotinib
by Zacks Equity Research
Gilead (GILD) and partner Galapagaos (GLPG) announces positive data on filgotinib for the treatment of psoriatic arthritis in adults and ulcerative colitis.
Pfizer's Arthritis Drug Gets FDA Nod for Ulcerative Colitis
by Zacks Equity Research
The FDA approves Pfizer's (PFE) sNDA seeking label expansion in third indication for Xeljanz to include moderately to severely active ulcerative colitis.
AstraZeneca (AZN) Stock on Growth Path This Year: Here's Why
by Zacks Equity Research
AstraZeneca's (AZN) stock is up this year while the Large-Cap Pharma industry is witnessing a decline
What's in Store for Cooper Companies' (COO) Q2 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) Q2 results are likely to reflect solid segmental growth; intense competition is a concern.
AbbVie (ABBV) Up 5.9% Since Earnings Report: Can It Continue?
by Zacks Equity Research
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint
by Zacks Equity Research
AbbVie's (ABBV) phase III iLLUMINA study evaluating Imbruvica in combination with Gazyva meets its primary endpoint of improvement in progression-free survival.
Is the Options Market Predicting a Spike in AbbVie (ABBV) Stock?
by Zacks Equity Research
Investors in AbbVie (ABBV) need to pay close attention to the stock based on moves in the options market lately.
Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis
by Zacks Equity Research
Eli Lilly (LLY) gets FDA approval for label expansion of its psoriasis injection Taltz to include data for psoriasis involving the genital area.
The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo
The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo
Roche (RHHBY) Announces Positive Data on Hemophilia Drug
by Zacks Equity Research
Roche (RHHBY) announces positive data from two phase III studies on hemophilia drug Hemlibra which has further strengthened its hemophilia portfolio.
Bear of the Day: Scotts Miracle-Gro (SMG)
by Madeleine Johnson
After disappointing earnings, can a budding marijuana business boost this lawncare stock?
Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV
by Zacks Equity Research
Gilead (GILD) announced dismal results for the first-quarter as HCV sales plunged further due to increasing competition.
Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More
by Zacks Equity Research
Four pharma/biotech companies are set to release earnings report on May 1. Let's take a look into how the companies are placed ahead of the upcoming results.
HIV Segment to Aid Gilead (GILD) Beat Q1 Earnings Estimates?
by Zacks Equity Research
Gilead (GILD) is likely to report an earnings beat in the first-quarter (results due on May 1) driven by its HIV franchise strength.
DaVIta (DVA) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Kidney Care Business and increasing number of dialysis centers are likely to boost DaVita's (DVA) earnings in Q1.
AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains
by Zacks Equity Research
AbbVie's (ABBV) Q1 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.
Is a Beat in the Cards for Gilead (GILD) in Q1 Earnings?
by Zacks Equity Research
Gilead (GILD) is likely to beat earnings estimates when it reports first-quarter results on May 1 driven by strong HIV sales.
AbbVie (ABBV) Tops Q1 Earnings and Revenues, View Up
by Debapriya Chakraborty
AbbVie's (ABBV) first-quarter 2018 earnings surpassed estimates with revenues marginally beating the same. Sales of its lead marketed drug Humira also increased compared to year ago figure.
What's in the Cards for Inogen (INGN) This Earnings Season?
by Zacks Equity Research
Inherent benefits of POCs, direct-to-customer business model, underpenetrated international markets and expanding product portfolio are key growth catalysts for Inogen (INGN) in Q1.
Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX
by Zacks Equity Research
Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.
Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?
by Zacks Equity Research
Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q1.